Aura Biosciences (NASDAQ:AURA) Raised to “Hold” at Wall Street Zen

Aura Biosciences (NASDAQ:AURA – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other research firms also recently commented on AURA. HC Wainwright dropped their target price on shares of Aura Biosciences from $24.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday, October 12th. Finally, Citigroup reissued a “market outperform” rating on shares of Aura Biosciences in a research report on Tuesday, November 10th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Aura Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $17.50.

Read Our Latest Analysis on AURA

Aura Biosciences Stock Performance

AURA stock opened at $7.11 on Friday. Aura Biosciences has a twelve month low of $4.73 and a twelve month high of $9.53. The company’s 50 day moving average is $6.54 and its two-hundred day moving average is $6.77. The stock has a market cap of $739.94 million, a P/E ratio of -4.34 and a beta of 0.42.

Aura Biosciences (NASDAQ:AURA – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.08. On average, equities research analysts predict that Aura Biosciences will post -1.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in AURA. Legal & General Group Plc purchased a new stake in Aura Biosciences in the second quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Aura Biosciences in the third quarter valued at approximately $33,000. Parallel Advisors LLC boosted its holdings in shares of Aura Biosciences by 130.4% in the first quarter. Parallel Advisors LLC now owns 5,665 shares of the company’s stock valued at $38,000 after acquiring an additional 3,206 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of Aura Biosciences during the second quarter worth approximately $54,000. Finally, ProShare Advisors LLC purchased a new position in shares of Aura Biosciences during the third quarter worth approximately $68,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

About Aura Biosciences

(Get Free Report)

Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area. Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.

Further Reading

Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.